Video
Dr. Ryan on the Long Term Safety of Abiraterone Use
Author(s):
Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.
Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.
The safety profile of abiraterone did not change much in subsequent analyses of COU-AA-302, Ryan says. The main adverse events associated with the agent were related to fluid retention, though there was potential for hypokalemia and liver dysfunction.
It was previously demonstrated that adverse events associated with corticosteroid use can be of concern in patients who remain on abiraterone. However, Ryan says, significant corticosteroid toxicities, such as osteoporotic fractures, were not any worse than what would be seen in the general population of patients.
<<<
